Geneos Wealth Management’s NovoCure NVCR Stock Holding History

Geneos Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.32K	Hold	213	–	–	﹤0.01%	2288
2025 Q4	$2.75K	Hold	213	–	–	﹤0.01%	2271
2025 Q3	$2.75K	Hold	213	–	–	﹤0.01%	2265
2025 Q2	$3.79K	Sell	213 -213	-50%	-$3.71K	﹤0.01%	2649
2025 Q1	$7.59K	Buy	+426	New	+$9.68K	﹤0.01%	2651
2023 Q4	–	Sell	-40	Closed	-$646	–	2147
2023 Q3	$646	Hold	40	–	–	﹤0.01%	2075
2023 Q2	$1.66K	Buy	+40	New	+$2.48K	﹤0.01%	1956
2022 Q4	–	Sell	-90	Closed	-$6K	–	2071
2022 Q3	$6K	Sell	90 -45	-33%	-$3.51K	﹤0.01%	1654
2022 Q2	$9K	Hold	135	–	–	﹤0.01%	2001
2022 Q1	$11K	Sell	135 -10	-7%	-$737	﹤0.01%	2056
2021 Q4	$10K	Buy	+145	New	+$14.6K	﹤0.01%	2184
2019 Q1	–	Sell	-200	Closed	-$6K	–	2450
2018 Q4	$6K	Buy	+200	New	+$7.31K	﹤0.01%	1943
2016 Q2	–	Sell	-100	Closed	-$1K	–	1830
2016 Q1	$1K	Buy	+100	New	+$1.44K	﹤0.01%	1738

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Geneos Wealth Management's NVCR Position: Q1 2026 in Review

Geneos Wealth Management held its NovoCure (NVCR) position steady in Q1 2026 at 213 shares worth $2.32K. The position accounts for ﹤0.01% of the portfolio, ranked #2288.

Geneos Wealth Management first reported a position in NVCR in Q1 2016 and has held it in 13 quarters since. The position peaked at $11K in Q1 2022. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Geneos Wealth Management held 213 shares of NovoCure worth $2.32K as of Q1 2026.
Geneos Wealth Management left its NovoCure share count unchanged in Q1 2026.
NovoCure made up ﹤0.01% of Geneos Wealth Management's portfolio in Q1 2026, its #2288 holding.
Geneos Wealth Management first reported a position in NovoCure in Q1 2016 and has held it in 13 quarters since.
Geneos Wealth Management's NovoCure position peaked at $11K in Q1 2022.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Geneos Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.